What is the difference between FDA registration and FDA approval for tissue products?

FDA registration indicates that a tissue bank or distributor has registered its facility under 21 CFR Part 1271 and submitted its product list. Section 361 HCT/Ps do not go through traditional pre-market drug approval (PMA or BLA); rather, they are regulated based on minimal manipulation and homologous use standards to prevent disease transmission.

How do I look up a tissue distributor's FDA Establishment Identifier (FEI)?

You can search the public FDA Human Cell and Tissue Establishment Registration (eLISS) database using the facility name or FEI number. A compliant distributor should readily provide their FEI and a copy of their active annual registration document upon request.

Is AATB accreditation legally required for tissue bank distributors?

While federal FDA regulations require registration and compliance with Current Good Tissue Practice (cGTP), formal accreditation by the American Association of Tissue Banks (AATB) is a voluntary third-party quality standard. However, many states and risk-conscious medical practices require AATB accreditation as an added layer of safety.

What documentation should accompany every biologic shipment?

Every shipment must include a Lot-Specific Certificate of Analysis (CoA) confirming donor screening, communicable disease testing compliance, sterility confirmation, and product verification. A detailed packing slip with lot numbers, expiration dates, and cold chain temperature monitoring indicators should also be included.

How to Verify Tissue Bank Accreditation and FDA Compliance

Medical practice managers and clinic administrators can verify tissue bank accreditation and FDA compliance by validating a distributor's active FDA Establishment Identifier (FEI) registration, confirming American Association of Tissue Banks (AATB) accreditation, and auditing lot-specific Certificates of Analysis (CoA) for all incoming orders. Ensuring that all human cells, tissues, and cellular and tissue-based products (HCT/Ps) strictly comply with 21 CFR Part 1271 guidelines protects practice licensure and safeguards clinical outcomes. Establishing a systematic vendor audit process mitigates regulatory liability and streamlines procurement workflows.

Understanding the Regulatory Framework for Biologic Distribution

Navigating the regulatory landscape for regenerative medicine requires a clear understanding of federal standards governing tissue processing and distribution. The U.S. Food and Drug Administration (FDA) regulates human cells, tissues, and cellular and tissue-based products under Title 21 of the Code of Federal Regulations, specifically Part 1271 (21 CFR Part 1271).

Within this framework, products are generally categorized under two regulatory pathways:

Section 361 HCT/Ps: Tissues that are minimally manipulated, intended for homologous use, and not combined with another article (with limited exceptions). These products do not require pre-market approval but must strictly adhere to Current Good Tissue Practice (cGTP) to prevent the introduction, transmission, or spread of communicable diseases.
Section 351 Products: Products that involve more than minimal manipulation, non-homologous use, or systemic action. These are regulated as drugs, devices, or biological products requiring pre-market approval, such as a Biologics License Application (BLA) or Investigational New Drug (IND) clearance.

Practice managers procuring biologics must verify that distributors operate within these precise definitions. Working with non-compliant suppliers exposes a medical clinic to severe legal, financial, and operational risks.

Step-by-Step Verification Checklist for Practice Administrators

To ensure your facility sources compliant, high-quality birth tissue allografts, amniotic fluids, or structural tissues, administrative teams should execute this verification protocol prior to issuing purchase orders:

Request and Verify the FDA Establishment Registration Number (FEI)

Obtain the distributor’s and manufacturer’s active FDA Form 3354 or electronic registration confirmation.
Cross-reference the FEI number in the FDA’s online Human Cell and Tissue Establishment Registration database to ensure the facility status is active and listed for the correct business functions (e.g., processing, storing, or distributing).

Confirm AATB Accreditation Status

Request a copy of the tissue bank’s current American Association of Tissue Banks (AATB) accreditation certificate.
Check the expiration date and scope of accreditation. AATB standards often exceed baseline federal requirements, offering independent confirmation of rigorous quality management systems.

Audit State License Documentation

Verify if your state (such as Texas, California, Florida, or New York) requires a specific tissue bank distributor license.
Ensure the distributor holds valid licenses in both their home state and the state where your practice operates.

Review the Standard Certificate of Analysis (CoA)

Examine a sample lot-specific CoA to confirm that donor screening includes testing for HIV-1/2, Hepatitis B (HBV), Hepatitis C (HCV), Syphilis, and HTLV-I/II.
Validate that testing was performed by a CLIA-certified or FDA-registered laboratory using FDA-cleared donor screening test kits.

Inspect Cold Chain and Logistics SOPs

Review the vendor’s Standard Operating Procedures for temperature monitoring during storage and transit (e.g., dry ice, liquid nitrogen phase, or controlled ambient ambient packaging).
Confirm that every delivery includes a calibrated temperature indicator or logging device.

Clinical Perspectives: What Physicians Need to Know About Tissue Sourcing

While administrators focus on workflow, invoices, and legal compliance, regenerative medicine doctors rely on distributor transparency to maintain clinical efficacy and patient safety.

For the treating physician, tissue integrity directly impacts patient care. Clinicians evaluating structural allografts or cellular solutions must assess:

Donor Screening Protocols: Beyond basic viral panels, reputable tissue banks conduct comprehensive medical and social history evaluations, physical assessments, and maternal medical records reviews (for birth tissues) to rule out behavioral or environmental risk factors.
Processing Methodologies: Minimal manipulation standards require that tissue processing preserves the original relevant characteristics relating to the tissue’s utility for reconstruction, repair, or supplementation. Physicians should ensure that processing methods avoid harsh chemical cross-linking or unapproved terminally destructive additives.
Homologous Use Standards: Clinicians must verify that the intended clinical application aligns with the biological tissue's structural function in the donor. Misrepresenting non-homologous applications can lead to regulatory scrutiny for the practice.

Open communication between clinical directors and practice administrators ensures that product selection fulfills both clinical objectives and compliance requirements.

Cold Chain Integrity and Lot Tracking Workflows

Receiving a shipment of biologics is not the end of the verification process; internal operational controls must track the tissue from delivery through clinical administration.

Receiving and Quarantine Protocols

Upon arrival, designated clinical staff must inspect the shipping container for physical damage and verify that the internal temperature indicator confirms proper environmental control during transit. Tissues should remain in a documented quarantine status until the packaging slip, lot numbers, and expiration dates are matched against the purchase order and lot-specific CoA.

Inventory Logging and Chart Integration

Under 21 CFR Part 1271, tissue tracking must allow complete traceability from the donor source to the patient recipient, or to final disposition if unused. Practice management software or specialized tissue logbooks must record:

Tissue description and manufacturer
Unique identifier / Lot number
Expiration date
Date and time of receipt
Date and time of clinical application
Patient identifier (medical record number)
Treating clinician signature

In the event of a manufacturer recall or inquiry, the practice must be capable of retrieving these records within hours.

What This Means for Your Practice

Establishing a formal vendor verification protocol prevents supply chain disruptions, avoids administrative sanctions, and builds patient confidence. To operationalize these standards, practice administrators should take three immediate steps:

Conduct an Audit of Existing Vendors: Request updated FDA registration documents, state licenses, and AATB certificates from all current biologic suppliers.
Update Intake SOPs: Implement a standardized receiving checklist that requires staff to verify temperature indicators and archive the Lot-Specific CoA before releasing inventory to procedure rooms.
Centralize Compliance Files: Maintain a digital compliance binder containing vendor credentials, standard operating procedures, and staff training records for easy access during regulatory inspections.

For additional answers regarding distributor documentation and state-specific licensing requirements, review our operational FAQ resources.

Partnering with Compliant Biologic Distributors

Sourcing high-purity, fully compliant biologics requires a distribution partner dedicated to regulatory transparency, rigorous cold-chain maintenance, and ongoing practice support. Since 2016, Dallas Regenerative Solutions has supplied licensed physicians and healthcare facilities with premium medical devices and biologics backed by complete documentation and compliant sourcing.

To review vendor compliance documentation or evaluate regenerative service line options for your facility, contact our team for an administrative consultation.